Rooney, Claire

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine

Protein Kinase Regulation and GTPase SignalingRNA Interference and Gene Delivery

Cited by 177

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study

Fizazi, K., Clarke, N. W., De Santis, M., Uemura, H., Fay, A. P., Karadurmus, N., Kwiatkowski, M., Alvarez-Fernandez, C., Jiang, S., Sotelo, M., et al. (2026) · Annals of Oncology

Prostate Cancer Treatment and ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 55

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity

Sacco, A., Federico, C., Todoerti, K., Ziccheddu, B., Palermo, V., Giacomini, A., Ravelli, C., Maccarinelli, F., Bianchi, G., Belotti, A., et al. (2021) · Blood

Multiple Myeloma Research and TreatmentsAcute Myeloid Leukemia Research

Cited by 20